RecruitingNCT07302802

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Sponsor

Prof. Dr. Martin Wabitsch

Enrollment

70 participants

Start Date

Dec 1, 2025

Study Type

OBSERVATIONAL

Conditions

Monogenic Obesity

Summary

This observational study aims to assess the effect of once-weekly s.c. semaglutide 2.4 mg as an adjunct to a calorie-reduced diet and increased physical activity on weight loss, change in hunger, body composition, depression, and quality of life after 68 weeks of treatment in adolescents diagnosed with monogenic obesity in routine clinical care.

Eligibility

Min Age: 12 YearsMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Semaglutide (administered by PDS290 pen-injector) for people with monogenic obesity. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 12 Years to 21 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSemaglutide (administered by PDS290 pen-injector)

Treatment with semaglutide as prescribed in routine clinical practice according to summary of product characteristics. The use of semaglutide can be categorised into two groups during enrolment period: 1. new users, or 2. current users (e.g., those continuing semaglutide treatment prescribed in routine clinical practice).

Locations(7)

Assistance Publique-Hôpitaux de Paris (AP-HP), Trousseau Hospital Paris, Pediatric Nutrition Department

Paris, France

Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin

Berlin, Germany

University Hospital for Children and Adolescents, Center for Pediatric Research, Medical Faculty, University of Leipzig

Leipzig, Germany

Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Centre

Ulm, Germany

University Medical Center Rotterdam, Erasmus MC-Sophia Children's Hospital

Rotterdam, Netherlands

Departments of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Universidad Autónoma de Madrid

Madrid, Spain

Wellcome-MRC Institute of Metabolic Science and NIHR Cambridge Biomedical Research Centre

Cambridge, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07302802

Related Trials

A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity

NCT063804262 locations

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

NCT072207721 location